Quick answer: IGF-1 LR3 and IGF-1 DES are both engineered or truncated variants of insulin-like growth factor 1 that bind poorly to IGF binding proteins, which makes them more potent than native IGF-1 in most cell-based assays. They get there by opposite routes. IGF-1 LR3 is longer than native IGF-1 (83 residues, with a 13-residue N-terminal extension and an arginine substitution at position 3), while IGF-1 DES is shorter (67 residues, missing the first three amino acids). That difference in architecture shapes how each one is used at the bench.
This comparison covers structure, binding-protein behavior, receptor signaling, published clearance data and practical handling. For laboratory research use only; not for human consumption.
What are IGF-1 LR3 and IGF-1 DES?
Native IGF-1 is a single-chain, 70-amino-acid polypeptide of about 7,649 Da, folded around three disulfide bonds. In serum and in conditioned culture media, almost all of it is bound to one of six high-affinity IGF binding proteins (IGFBP-1 through IGFBP-6). Those binding proteins act as a reservoir and a buffer: they extend the time IGF-1 persists in circulation, but they also limit how much free ligand reaches the IGF-1 receptor (IGF-1R).
Both analogs discussed here were characterized largely by Australian groups in the late 1980s and early 1990s who were asking a simple question: what happens to IGF-1 activity when binding-protein interactions are removed?
- IGF-1 LR3 (Long R3 IGF-1, also written LONG R3 IGF-I) is a recombinant analog designed for that purpose and later adopted widely as a cell-culture media supplement.
- IGF-1 DES (des(1-3) IGF-1) is a naturally occurring truncated form first isolated from bovine colostrum and from human brain tissue, and subsequently produced synthetically or recombinantly for research.
IGF-1 LR3 vs IGF-1 DES at a glance
| Property | Native IGF-1 | IGF-1 LR3 | IGF-1 DES (1-3) |
|---|---|---|---|
| Length | 70 amino acids | 83 amino acids | 67 amino acids |
| Approx. molecular weight | ≈ 7.65 kDa | ≈ 9.11 kDa | ≈ 7.37 kDa |
| Modification | None | Glu3→Arg substitution plus 13-residue N-terminal extension | Deletion of N-terminal Gly-Pro-Glu |
| Origin | Endogenous | Engineered recombinant analog | Naturally occurring truncated variant |
| IGFBP affinity | High | Very low | Very low (markedly reduced for most IGFBPs) |
| IGF-1R binding | Reference | Similar to slightly lower | Similar |
| Reported in vitro potency vs IGF-1 | 1× | Roughly 3× in many cell assays | Roughly 10× in many cell assays |
| Typical laboratory role | Reference ligand | Serum-free media supplement; sustained IGF-1R stimulation | Short-exposure and local-signaling experiments; IGFBP-independence controls |
Potency multiples depend heavily on the cell line and on how much binding protein that cell line secretes. In a system with little IGFBP present, all three ligands converge toward similar activity.
Structural differences
IGF-1 LR3: an extension plus a substitution
IGF-1 LR3 carries two changes relative to the native sequence. First, the glutamic acid at position 3 is replaced with arginine (the "R3"). Second, a 13-amino-acid peptide is fused to the N-terminus (the "Long"); the extension derives from the N-terminal region of porcine growth hormone followed by a short linker, and was originally included to improve recombinant expression. The result is an 83-residue protein of roughly 9.1 kDa. Because it is closer to a small protein than a short peptide, it is commonly supplied in small vial sizes such as the 1 mg IGF-1 LR3 research vial.
The Glu3 residue matters because it sits in the region of IGF-1 that contacts the binding proteins. Swapping its negative charge for a positive one, and placing a bulky extension next to it, sharply reduces IGFBP affinity while leaving the receptor-binding surface largely intact.
IGF-1 DES: a three-residue truncation
IGF-1 DES lacks the N-terminal tripeptide glycine-proline-glutamate. It is thought to arise in tissue through post-translational proteolytic processing of full-length IGF-1. The truncation removes the same Glu3 residue that LR3 mutates, which is why the two analogs share the low-IGFBP-binding phenotype despite looking very different on paper. At 67 residues and about 7.37 kDa, des(1-3) IGF-1 is the smallest of the three molecules and retains all three disulfide bonds of the parent structure.
Why IGF binding proteins are the key variable
Most cultured cells secrete IGFBPs into their medium. When native IGF-1 is added to such a culture, a large fraction is captured by those binding proteins before it reaches IGF-1R. Analogs that evade capture deliver more free ligand per unit added, and so appear more potent.
- IGF-1 DES shows greatly reduced binding to several IGFBPs, and early work in myoblast and fibroblast systems reported roughly a tenfold increase in potency over IGF-1 for stimulating protein and DNA synthesis.
- IGF-1 LR3 shows even lower IGFBP affinity in some assays, but its receptor affinity is modestly lower than that of native IGF-1. The net effect in the original characterization studies was a potency gain of about threefold, though higher multiples are reported in cell lines that secrete abundant binding protein.
This is also the reason either analog can serve as an experimental control. If a response to native IGF-1 is weak but the response to a low-IGFBP analog is strong, binding-protein sequestration is a likely explanation.
Receptor signaling
Neither analog changes which receptor is engaged. Both act through IGF-1R, a receptor tyrosine kinase that autophosphorylates on ligand binding and recruits insulin receptor substrate (IRS) adaptor proteins. Two downstream branches dominate the literature:
- PI3K–Akt–mTOR, associated in cell models with protein synthesis, glucose uptake and survival signaling.
- Ras–Raf–MEK–ERK, associated with proliferation and differentiation programs.
Like IGF-1 itself, both analogs can also activate the insulin receptor and hybrid receptors at high concentrations, which is worth controlling for when working well above the nanomolar range.
Persistence and clearance: what the literature actually shows
Online summaries frequently state that IGF-1 LR3 persists for 20 to 30 hours and IGF-1 DES for 20 to 30 minutes. Those figures are widely repeated but are not well anchored in primary pharmacokinetic studies, and researchers should be cautious about designing experiments around them.
What the published animal work supports is more nuanced. Native IGF-1 owes its long circulating residence to the ternary complex it forms with IGFBP-3 and the acid-labile subunit; free IGF-1 is cleared within minutes. In rat studies from the early 1990s, analogs with reduced binding-protein affinity, including both LR3 and des(1-3) IGF-1, were cleared from plasma faster than native IGF-1, precisely because they were not held in that complex. Yet the same analogs were more potent than IGF-1 in rodent growth models, consistent with greater delivery of free ligand to tissue.
Two practical conclusions follow:
- In cell culture, LR3 is valued for stable, sustained receptor stimulation over multi-day culture periods, which reflects its resistance to sequestration and its good stability in media rather than any in vivo half-life figure.
- DES is the smaller, more rapidly acting ligand and is usually chosen for acute stimulation experiments and for models of local, tissue-level IGF processing.
How each analog is used in laboratory work
IGF-1 LR3
The dominant application is as a growth-factor supplement in serum-free and chemically defined media. It is used in place of insulin or native IGF-1 to support mammalian cell lines, including CHO cells in bioprocess development, typically at working concentrations in the tens of ng/mL. It is also a standard tool in myoblast proliferation and differentiation assays, hypertrophy models in C2C12 myotubes, and studies of IGF-1R signaling kinetics.
IGF-1 DES
Because des(1-3) IGF-1 is an endogenous processing product, it features in research on tissue-specific IGF-1 activation, particularly in brain, uterine and colostrum-related studies. It is also used as a high-potency ligand for short-duration receptor stimulation, and in side-by-side designs that test whether binding proteins modulate a given response. The cleaved tripeptide (Gly-Pro-Glu) is a research subject in its own right in neuroscience literature.
Handling, reconstitution and storage
Both molecules are disulfide-bonded proteins and deserve gentler handling than short linear peptides.
- Reconstitution: follow the solvent stated on the supplier datasheet. Add diluent slowly down the vial wall and swirl gently; do not vortex. General technique is covered in how to mix peptides with bacteriostatic water.
- Concentration math: 1 mL of diluent added to a 1 mg vial gives 1 mg/mL (1,000 µg/mL), about 110 µM for LR3. A 1:10,000 serial dilution of that stock yields 100 ng/mL. The calculator can be used to check stock and working figures.
- Adsorption: at low concentrations, IGF analogs stick to glass and plastic. Low-protein-binding tubes, and a carrier protein such as BSA in working dilutions where the assay allows, reduce losses.
- Storage: keep lyophilized vials at −20 °C, refrigerate reconstituted stock at 2–8 °C for short-term work, and freeze single-use aliquots to avoid repeated freeze–thaw cycles. See storing research peptides for the general framework.
- Documentation: confirm identity and purity against the batch certificate on the COA page before starting an experiment series.
Choosing between them for a study design
The choice usually comes down to exposure pattern and to what question the experiment is asking.
- Choose IGF-1 LR3 for long-duration culture, media supplementation, and any design that needs steady IGF-1R activation across days with minimal interference from secreted IGFBPs.
- Choose IGF-1 DES for acute time-course experiments, maximal potency per mole in high-IGFBP systems, or studies of endogenous IGF-1 processing.
- Include native IGF-1 alongside either analog when the aim is to quantify how much binding proteins are shaping the response.
Readers new to the category can start with what research peptides are, and the current catalog is listed in the shop.
Frequently asked questions
Is IGF-1 LR3 the same as IGF-1 DES?
No. LR3 is an 83-residue engineered analog with an N-terminal extension and an arginine substitution at position 3. DES is a 67-residue truncated form missing the first three residues. They share one functional trait, low affinity for IGF binding proteins, but differ in size, origin and typical laboratory application.
Which is more potent in cell assays?
In the original characterization studies, des(1-3) IGF-1 was roughly ten times more potent than native IGF-1 and LR3 roughly three times more potent. The exact multiple varies by cell line because it depends on how much binding protein the cells secrete.
Why is IGF-1 LR3 so common in cell culture media?
It activates IGF-1R at low concentrations, resists sequestration by secreted binding proteins, and remains stable across multi-day cultures. Those properties made it a practical substitute for insulin in serum-free and chemically defined media formulations.
Do the two analogs signal through different receptors?
No. Both act primarily through IGF-1R and its downstream PI3K–Akt and MAPK/ERK branches. As with native IGF-1, cross-activation of the insulin receptor can occur at high concentrations, so concentration-response controls are advisable.